Abstract

This retrospective study was carried out to evaluate disease free interval (DFI) and survival time of cats with mammary carcinomas that underwent mastectomy (RM) and adjuvant chemotherapy (RMAC) in 35 cats to remove the neoplastic mammary chain and regional inguinal lymphadenectomy. According to performed treatment, the cats were divided into two groups. The RM group (21 cats) received no adjuvant therapy, and the RMAC group (14 cats) received chemotherapy with mitoxantrone or doxorubicin. Histopathological margins were considered complete in all cases. Eight cats had histologically confirmed lymph node involvement at the time of surgery. Three cases were classified as stage I, 21 cases as II and eight cases as III. Nine cats had tumor recurrence (four cats of RM group and five cats of RMAC group) and 12 cats had distant metastasis to the lungs (six cats of each group). Mean and median survival times were 1625 and 2404 days in the RM group, while mean DFI was 815 days. In RMAC group, mean and median survival times were 719 and 690 days, while mean DFI was 549 days. Surgery remains the main treatment and more studies are necessary to evaluate the benefit of adjuvant chemotherapy.